

Collaborative Study of Bacterial Endotoxins Test Using Recombinant Factor C–Based Procedure for Detection of Lipopolysaccharides (Part 3)

Yutaka KIKUCHI^{*1, #}, Masashi MUROI^{*2}, Yukari NAKAGAWA^{*3}, Akiko EBISAWA^{*3}, Mayumi HAYASHI^{*3}, Honoka TAKEUCHI^{*3}, Yuka KIWAMOTO^{*3}, Kayoko MATSUMURA^{*4}, Rumiko YOSHIMOTO^{*5}, Natsuko TSUZUKI^{*5}, Nayoko OIKAWA^{*5}, Mina HASHIMOTO^{*5}, Yoriko HIRAMATSU^{*5}, Miki FUKAMI^{*6}, Kazuya KOBAYASHI^{*6}, Narumi SANDA^{*6}, Syuhei ETO^{*6}, Mitsuo MORI^{*6}, Olivier MARTINEZ^{*7}, Masato SUZUKI^{*7}, Sachie SEKIGUCHI^{*7}, Kazuyuki OUCHI^{*8}, Hiroki FUKUCHI^{*9}, Takeshi KITAGAWA^{*10}, Motoi KIZAWA^{*10}, Tamaki MASUDA^{*11}, Toshio ODA^{*12}, Hikaru MIZUMURA^{*12}, Norihiko OGURA^{*12}, Daizaburo IIDA^{*13}, Kanako SUEOKA^{*13}, Yuji TANNO^{*13} and Masakazu TSUCHIYA^{*14}

(Received: January 30, 2023; Accepted: May 18, 2023)

Summary

Two new recombinant cascade reagents (rCRs), PyroSmart NextGen[®] and PYROSTAR[™] Neo, have recently become available for endotoxin testing of parenteral drugs in the Japanese market. This study investigated whether these two rCRs, as well as the current commercially available recombinant factor C reagents (rFCs) PyroGene[™] and EndoZyme[®] II, can be used as alternative reagents to the amoebocyte lysate reagents currently used in the compendial Bacterial Endotoxins Test. The two rFCs were investigated in the previous two-year study.

An *Escherichia coli* O113: H10: K negative culture supernatant and seven water samples (six different tap waters and one deionized water) were tested for autochthonous endotoxin, and the endotoxin levels detected with four amoebocyte

-
- * 1 Department of Nutrition, Faculty of Healthcare Sciences, Chiba Prefectural University of Health Sciences, 2-10-1 Wakaba, Mihama-ku, Chiba, Chiba 261-0014, Japan
 - * 2 Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishitokyo, Tokyo 202-8585, Japan
 - * 3 Pharmaceutical Reference Standards Center, Pharmaceutical and Medical Device Regulatory Science Society of Japan, 2-1-2 Hiranomachi, Chuo-ku, Osaka 541-0046, Japan
 - * 4 Section of Biological Safety Research, Chitose Laboratory, Japan Food Research Laboratories, 2-3 Bunkyo, Chitose-shi, Hokkaido 066-0052, Japan
 - * 5 Section of Biological Science, Chitose Laboratory, Japan Food Research Laboratories, 2-3 Bunkyo, Chitose-shi, Hokkaido 066-0052, Japan
 - * 6 Quality Control Department, Takasaki Quality Unit, Quality Division, Kyowa Kirin Co.,Ltd., 100-1 Hagiwara-machi, Takasaki-shi, Gunma 370-0013, Japan
 - * 7 Industry Business Unit, bioMérieux Japan Ltd., 2F Akasaka Tameike Tower, 2-17-7 Akasaka, Minato-ku, Tokyo 107-0052, Japan
 - * 8 J.K. International, Inc., 3-1-7 Nihonbashikayabacho, Chuo-ku, Tokyo 103-0025, Japan
 - * 9 Production Process Development Department, FUJIFILM Wako Pure Chemical Corporation, 6-1, Takada-cho, Amagasaki-shi, Hyogo 661-0963, Japan
 - * 10 LAL Development Department, FUJIFILM Wako Pure Chemical Corporation, 1-2, Doshomachi 3-Chome, Chuo-ku, Osaka 540-8605, Japan
 - * 11 Lonza K.K., 9th floor, Nihonbashi Kato Building 1-14, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-0027, Japan
 - * 12 LAL Research, Central Research Laboratory, Seikagaku Corporation, 3-1253 Tateno, Higashiyamato-shi, Tokyo 207-0021, Japan
 - * 13 Bioscience Department, Veritas Corporation, 1-18-16 Hamamatsucho, Minato-ku, Tokyo 105-0013, Japan
 - * 14 Charles River, 1023 Wappoo Road, Suite 43B, Charleston, SC 29407, USA
 - # Corresponding author

lysates and four recombinant protein reagents were compared. The results indicate that the four recombinant protein reagents can detect autochthonous endotoxin in culture supernatant samples at levels comparable (within the 50%–200% range as defined in the Pharmacopeias) to those measured with limulus amoebocyte lysate reagents. One of the four recombinant reagents detected autochthonous endotoxin in water at comparable levels to those obtained with lysate reagents in all samples, whereas the other three reagents detected comparable or lower levels among different samples. These findings suggest that there are differences in the detectability of autochthonous endotoxin in water among the recombinant protein reagents.

Key words

Bacterial endotoxin test, Amoebocyte lysate reagent, Recombinant factor C reagent, Recombinant cascade reagent

1. Introduction

Endotoxin (also referred to as lipopolysaccharide, LPS) in the cell walls of Gram-negative bacteria is a strongly pyrogenic substance that can activate innate immune responses¹⁾. Trace amounts of endotoxin directly invading the bloodstream can induce fever, and larger amounts can lead to life-threatening septic shock. Therefore, methods to detect endotoxin contamination in products are critical. The Bacterial Endotoxins Test (BET) is listed in chapter 4.01 of the Japanese Pharmacopoeia eighteenth edition (JP 18)²⁾ as a method to test endotoxin contamination in parenteral drugs.

The BET harmonized among the JP, the European Pharmacopoeia (Ph. Eur.)³⁾ and the United States Pharmacopoeia (USP)⁴⁾ is a method to detect or quantitate endotoxin using amoebocyte lysate reagent (*Limulus* amoebocyte lysate, LAL or *Tachypleus* amoebocyte lysate, TAL) prepared by extraction of hemocytes from horseshoe crabs (*Limulus polyphemus* or *Tachypleus tridentatus*). The BET has three different methodologies: one is the gel-clot assay, which involves visual observation of gel formation; the second is a turbidimetric assay that measures the time required to reach a threshold optical density caused by changes in turbidity; and the last is a colorimetric assay, which measures optical color development resulting from cleavage of a synthetic substrate from a peptide.

Over the last several years, rFCs comprising only recombinant factor C, an endotoxin-sensitive serine protease zymogen, have been developed and introduced to the market to aid in the conservation of the horseshoe crab, provide a stable supply of reagent, and improve the consistency of testing results by eliminating the biological lot-to-lot variability of amoebocyte lysate reagents⁵⁾. Lonza and Hyglos/bioMérieux developed and introduced the recombinant protein reagents, PyroGeneTM and EndoZyme[®], respectively, to the market. Each reagent contains a single recombinant zymogen protease (factor C) from horseshoe crabs. PyroGeneTM has factor C from *Carcinoscorpius rotundicauda*, whereas EndoZyme[®] contains *T. tridentatus* factor C⁶⁾. Recently, a recombinant cascade reagent (rCR), PyroSmart NextGen[®], comprising rFC, recombinant factor B and recombinant proclotting enzyme, was developed and introduced to the market by Associates of Cape Cod, Inc. and Seikagaku Corporation⁷⁾. This was followed by another rCR, PYROSTARTM Neo, from FUJIFILM Wako Pure Chemical Corporation. Both rCRs use recombinant factors from *L. polyphemus*. Cascade reactions of amoebocyte lysate (panel A), rFC (panel B) and rCR (panel C) reagents in the presence of endotoxin are shown in Fig. 1. These recombinant protein reagents cannot be used for BET as described in the Pharmacopeias, since an amoebocyte lysate prepared from blood corpuscle




Fig. 1 Cascade Reactions of (A) Amoebocyte Lysate, (B) Recombinant Factor C and (C) Recombinant Cascade Reagents.

extracts of horseshoe crabs (*L. polyphemus* or *T. tridentatus*) must be used²⁾. However, the US Food and Drug Administration (FDA)⁸⁾ states that rFC-based procedures can be used to test endotoxin as an alternative method to the BET⁴⁾ after validation in accordance with USP Chapter <1225> Validation of Compendial Procedures⁹⁾. The Ph. Eur. also states that rFCs can be used as compendial methods after validation¹⁰⁾. In June 2021, the JP 18 issued Bacterial endotoxins test and alternative methods using recombinant protein-reagents for endotoxin assay <G4-4-180>¹¹⁾ as General Information, permitting alternative methods to be adopted after validation. However, in Japan validation of recombinant protein reagents to replace amoebocyte lysate reagents has so far been limited due to lengthy discussions surrounding different approaches for implementing alternative analytical procedures by end-users and manufacturers^{7, 12-16)}.

So far, the appropriateness of using recombinant protein reagents to test endotoxin as alternative methods to the BET has been evaluated in two studies in 2017¹⁷⁾ and 2018¹⁸⁾. Those studies concluded that recombinant protein reagents have lot-to-lot consistency and similar performance relative to amoebocyte lysate reagents when

testing the reactivity to LPS purified from several different species of bacteria as well as autochthonous endotoxin [called naturally occurring endotoxin (NOE) in the study reports].

In this study, the performance of the two newly available rCRs in Japan as well as the existing rFCs was compared to that of four amoebocyte lysate reagents for the detection of autochthonous endotoxin in water, which is used as a raw material for parenteral drugs, and in culture supernatant of *E. coli* O113: H10: K negative, which is the same bacterial strain as that used to provide a reference standard endotoxin by the JP, USP and Ph. Eur. Furthermore, *E. coli* O113: H10: K negative is also used by the World Health Organization (WHO) as an international reference standard.

2. Materials and Methods

Apparatus

All glassware was washed and then depyrogenated in a hot-air oven using a validated process. Plastic materials, such as multi-well plates and tips for micropipettes, were used after they had been determined to be free of detectable endotoxin and to cause no interference with the

test.

Endotoxin

JP-Reference Standard Endotoxin (JP-RSE) was purchased from the Pharmaceutical and Medical Device Regulatory Science Society of Japan (PMRJ, Osaka, Japan).

Water samples

Six tap water samples and one deionized water sample were collected from the seven institutes that participated in this study. After collection, each water sample was aliquoted into tubes, and the aliquots were kept frozen at -80°C until use.

Preparation of culture supernatant of *Escherichia coli* O113: H10: K negative

E. coli O113: H10: K negative was cultured according to the reported method¹⁹⁾ with some modifications. Briefly, the culture medium was a minimal microbial growth medium containing sodium phosphate (dibasic), monopotassium phosphate, sodium chloride, ammonium chloride, glucose, magnesium sulfate and calcium chloride. After culturing, the medium was centrifuged at $2,330 \times g$ for 5 min at 4°C to separate the culture supernatant. The supernatant was sterilized by filtration through a membrane filter with a pore size not exceeding $0.22 \mu\text{m}$ (Merck code # S2GPU05RE, Darmstadt, Germany) and kept frozen at -80°C until use.

Amoebocyte lysate reagents

Endochrome-KTM with endotoxin-specific reconstitution buffer was purchased from Charles River Laboratories (MA, USA). Endospecy[®] ES-50M was purchased from Seikagaku Corporation (Tokyo, Japan) and Kinetic-QCLTM was purchased from Lonza (MD, USA). PYROSTARTM ES-F was purchased from FUJIFILM Wako Pure Chemical Corporation (Tokyo, Japan).

Recombinant protein reagents

As rFCs, EndoZyme[®] II was purchased from Hyglos/bioMérieux (Munich, Germany) and PyroGeneTM was purchased from Lonza (MD, USA). As rCRs, PyroSmart NextGen[®] was purchased from Associates of Cape Cod, Inc. (MA,

USA) and PYROSTARTM Neo was purchased from FUJIFILM Wako Pure Chemical Corporation (Tokyo, Japan). PyroSmart NextGen[®] was used both in onset time assay, which measures the time required to reach a threshold absorbance, and rate assay, which measures the mean rate of color development, unless otherwise mentioned.

Endotoxin Assay

Endotoxin in the water samples and culture supernatant was measured using amoebocyte lysate and recombinant protein reagents. All reagents were used according to their Instructions for Use (IFU). JP-RSE was employed as a standard, and three two-fold dilution series were prepared with the following concentrations: 0.125, 0.0625, 0.03125, 0.015625 and 0.0078125 endotoxin unit (EU)/mL. Autochthonous endotoxin in water samples and culture supernatants was measured after dilution according to the following scheme: tap water #1: 50- and 500-fold, tap water #2: 3- and 30-fold, deionized water #1: 5- and 50-fold, tap water #3-#6: 5- and 50-fold, culture supernatant: 5×10^5 - and 5×10^6 -fold. All water samples and the culture supernatant were tested with all amoebocyte lysate and recombinant protein reagents at three institutions: PMRJ, Japan Food Research Laboratories (JFRL) and Kyowa Kirin Co., Ltd. All water samples and the culture supernatant were subjected to testing with PyroSmart NextGen[®] in onset time assay and with PYROSTARTM Neo at Musashino University. All water samples and culture supernatant were tested at participating institutions other than those mentioned above using their own amoebocyte lysate and recombinant protein reagents.

Data analysis

F-test was conducted using Excel 2019 (Microsoft, Tokyo, Japan) with the software OriginPro 2022 (Lightstone, Tokyo, Japan).

3. Results

Water and culture supernatant samples were

Table 1 Evaluation of Endotoxin Panel Using Amoebocyte Lysate Reagent

No.	sample	Endochrome-K				Endospey ES-50M			
		EU/mL ^a	RSD (%) ^b	50%Min - 200%Max ^c	n ^d	EU/mL	RSD (%)	50%Min - 200%Max	n
<i>Autochthonous endotoxin</i>									
1	<i>Escherichia coli</i> O113:H10:K negative	45880 ± 2386	10.40	20790 - 100100	4	46800 ± 2815	12.03	20030 - 107300	4
<i>Water including endotoxin</i>									
2	Tap water #1	16.27 ± 1.763	21.67	5.773 - 39.93	4	15.50 ± 2.458	31.71	5.219 - 43.92	4
3	Tap water #2	0.1845 ± 0.008788	9.524	0.07930 - 0.3940	4	0.1935 ± 0.01555	16.08	0.07930 - 0.4680	4
4	Deionized water #1	3.692 ± 0.3117	16.88	1.473 - 8.826	4	2.926 ± 0.2375	16.24	1.156 - 6.918	4
5	Tap water #3	3.129 ± 0.2702	17.27	1.228 - 7.555	4	2.489 ± 0.3091	24.84	0.8084 - 6.066	4
6	Tap water #4	3.057 ± 0.2476	16.20	1.161 - 6.792	4	2.507 ± 0.07016	5.596	1.150 - 5.192	4
7	Tap water #5	1.380 ± 0.1206	17.47	0.5832 - 3.437	4	0.9623 ± 0.05614	11.67	0.3998 - 2.079	4
8	Tap water #6	0.7609 ± 0.06782	17.83	0.3198 - 1.761	4	0.8142 ± 0.06737	16.55	0.3365 - 1.980	4
No.	sample	Kinetic-QCL				PYROSTAR ES-F			
		EU/mL	RSD (%)	50%Min - 200%Max	n	EU/mL	RSD (%)	50%Min - 200%Max	n
<i>Autochthonous endotoxin</i>									
1	<i>Escherichia coli</i> O113:H10:K negative	60250 ± 4732	15.71	27000 - 148000	4	47980 ± 5148	21.46	20120 - 126300	4
<i>Water including endotoxin</i>									
2	Tap water #1	14.99 ± 2.470	32.95	4.500 - 40.20	4	11.44 ± 1.224	21.41	4.358 - 28.90	4
3	Tap water #2	0.2326 ± 0.03955	34.01	0.08055 - 0.6600	4	0.1700 ± 0.01445	17.00	0.07680 - 0.4265	4
4	Deionized water #1	4.155 ± 0.6370	30.66	1.505 - 11.00	4	3.044 ± 0.1522	9.999	1.422 - 6.986	4
5	Tap water #3	2.809 ± 0.4239	30.18	1.0280 - 7.980	4	3.072 ± 0.2619	17.05	1.339 - 7.600	4
6	Tap water #4	3.644 ± 0.3677	20.18	1.386 - 8.980	4	2.920 ± 0.2633	18.04	1.170 - 6.987	4
7	Tap water #5	1.233 ± 0.04630	7.513	0.5525 - 2.640	4	1.119 ± 0.02161	3.863	0.5360 - 2.350	4
8	Tap water #6	1.078 ± 0.1326	24.61	0.4675 - 2.950	4	0.5857 ± 0.05223	17.84	0.2304 - 1.433	4

^a Values shown are mean ± standard error of results from participating independent institutions.

^b Relative standard deviation.

^c Range between 50% of minimum and 200% of the maximum the levels detected with amoebocyte lysate reagent.

^d Number of institutions that carried out measurements.

tested for autochthonous endotoxin with four amoebocyte lysate reagents and four recombinant protein reagents. The mean and standard error for each reagent were calculated, and the results are shown in Tables 1 and 2, and Fig. 2 and 3. Autochthonous endotoxin was detected in all water samples and the culture supernatant with both amoebocyte lysate and recombinant protein reagents. As shown by *F*-test analysis, autochthonous endotoxin levels detected with both amoebocyte lysate and recombinant protein reagents showed equal reagent-to-reagent variance among all samples, with the exception of culture supernatant (Table 3).

4. Discussion

In this study and the two previous studies^{17, 18)}, the appropriateness of using recombinant protein reagents to test endotoxin as an alternative method to the BET was evaluated by ten institutions.

Autochthonous endotoxin in both culture supernatant and water samples was detected with both amoebocyte lysate and recombinant protein reagents with acceptable repeatability and reproducibility. Moreover, for each sample measured at three or more institutions, inter-institutional differences between recombinant and amoebocyte lysate reagents were similar, suggesting that there was no difference in

Table 2 Evaluation of Endotoxin Panel Using Recombinant Protein Reagent

No.	sample	EndoZyme II			PyroGene			PyroSmart NextGen-onset time		
		EU/mL ^a	RSD (%) ^b	<i>n</i> ^c	EU/mL	RSD (%)	<i>n</i>	EU/mL	RSD (%)	<i>n</i>
<i>Autochthonous endotoxin</i>										
1	<i>Escherichia coli</i> O113:H10:K negative	113500 ± 1189	2.095	4	47640 ± 5043	21.17	4	54700 ± 3176	12.99	5
<i>Water including endotoxin</i>										
2	Tap water #1	2.386 ± 0.3271	27.42	4	4.205 ± 0.7796	37.08	4	15.40 ± 1.444	20.97	5
3	Tap water #2	0.02861 ± 0.0009355	6.539	4	0.03048 ± 0.001705	11.19	4	0.1890 ± 0.01822	21.56	5
4	Deionized water #1	1.647 ± 0.03545	4.304	4	1.759 ± 0.1825	20.75	4	3.230 ± 0.3885	26.89	5
5	Tap water #3	0.4557 ± 0.1028	45.11	4	0.7513 ± 0.05651	15.04	4	2.600 ± 0.2012	17.31	5
6	Tap water #4	0.7006 ± 0.05401	15.42	4	0.8350 ± 0.08132	19.48	4	2.940 ± 0.1654	12.58	5
7	Tap water #5	0.3460 ± 0.02350	13.59	4	0.2966 ± 0.01731	11.67	4	0.8130 ± 0.05953	16.37	5
8	Tap water #6	0.1462 ± 0.02364	32.35	4	0.06563 ± 0.007883	24.02	4	0.7900 ± 0.05788	16.38	5
No.	sample	PyroSmart NextGen-rate			PYROSTAR Neo					
		EU/mL	RSD (%)	<i>n</i>	EU/mL	RSD (%)	<i>n</i>			
<i>Autochthonous endotoxin</i>										
1	<i>Escherichia coli</i> O113:H10:K negative	50820 ± 2981	10.16	3	74920 ± 5946	17.75	5			
<i>Water including endotoxin</i>										
2	Tap water #1	14.31 ± 2.165	26.20	3	10.47 ± 1.774	37.89	5			
3	Tap water #2	0.1491 ± 0.008495	9.867	3	0.04996 ± 0.002622	11.74	5			
4	Deionized water #1	3.929 ± 0.09098	4.011	3	3.198 ± 0.2781	19.45	5			
5	Tap water #3	2.846 ± 0.3591	21.86	3	1.289 ± 0.1465	25.42	5			
6	Tap water #4	2.772 ± 0.1125	7.026	3	1.626 ± 0.2486	34.19	5			
7	Tap water #5	0.7927 ± 0.01538	3.360	3	0.4279 ± 0.03375	17.64	5			
8	Tap water #6	0.6314 ± 0.1053	28.87	3	0.3122 ± 0.02964	21.23	5			

^a Values shown are mean ± standard error of results from participating independent institutions.

^b Relative standard deviation.

^c Number of institutions that carried out measurements.

reproducibility.

The reagent-to-reagent variability among the four amoebocyte lysate reagents in detecting the autochthonous endotoxin level in each water sample and *E. coli* culture supernatant was 1.26-fold at minimum (Endochrome-K/Endospecy ES-50M in tap water #3) and 1.84-fold at maximum (Kinetic-QCL/PYROSTAR ES-F in tap water #6). Among the four recombinant protein reagents, the reagent-to-reagent variability was 2.38-fold at minimum (EndoZyme II/PyroGene for the culture supernatant) and 12.04-fold at maximum (PyroSmart NextGen-onset time/PyroGene for tap water #6). Some recombinant protein reagents exhibited lower detectability of autochthonous endotoxin in water samples.

In this study, we adopted the BET assay variability of 50%–200% as defined in the Pharmacopeias to investigate the comparability of endotoxin levels in samples detected by recombinant protein reagents and by the amoebocyte lysate reagents. Endotoxin levels detected by recombinant protein reagents falling within the 50%–200% range of the respective lysate reagents were considered comparable for the present purpose. PyroSmart NextGen[®] detected autochthonous endotoxin in all seven water samples and the culture supernatant sample at comparable levels. PyroGene[™] and EndoZyme[®] II detected autochthonous endotoxin in two samples, deionized water #1 and the culture supernatant, at levels comparable to the lysate




Fig. 2 Comparison of Amoebocyte Lysate and Recombinant Protein Reagents for Detection of Autochthonous Endotoxin

Culture supernatant of *Escherichia coli* O113:H10: K negative was measured with various amoebocyte lysate (■) and recombinant protein reagents (□). The relative endotoxin activities (EU/mL) against RSE were calculated to compare the specificity of each reagent. Values are the mean ± standard error shown in Tables 1 and 2.

reagents levels. PYROSTAR™ Neo detected autochthonous endotoxin in six samples (tap water #1, 3, 4, 5 and 6, deionized water #1) and culture supernatant at comparable levels. This tendency of rFCs to detect lower levels of autochthonous endotoxin in tap and deionized water than those measured with lysate reagents was observed in our first study in 2017¹⁷⁾ and was previously described⁷⁾. The reason for the difference in detectability of autochthonous

endotoxin in water between rFCs and rCRs is not clear. However, one possibility is that it might depend upon whether or not factor B is included in the recombinant protein reagents. Factor B is reported to participate in the recognition of endotoxin as well as in signal transduction within the cascade²⁰⁾. The slight differences in endotoxin detection with PyroSmart NextGen® and PYROSTAR™ Neo, which are both rCRs, might be ascribed to differences of other formulation components in those reagents. Nevertheless, the detectability of autochthonous endotoxin in the culture supernatant of *E. coli* O113: H10: K negative and most purified LPS from several types of bacteria in the previous two-year study^{17, 18)} by recombinant protein reagents was comparable to that with the four amoebocyte lysate reagents. The same tendency, including low measured potency of LPS such as *Helicobacter pylori* LPS, is also reported by another group⁷⁾. These findings may suggest that autochthonous endotoxin in tap and deionized water is less able to associate with or activate factor C, compared to standard endotoxin. Further studies may be necessary to elucidate why the relative detectability of endotoxin by recombinant protein reagents and by amoebocyte lysate reagents varies depending on the origin of the endotoxin.

When selecting a commercially available recombinant protein reagent to be used for testing endotoxin, it is recommended that end-users consider aspects of product quality and development, in addition to the performance of rFC¹²⁾ or rCR¹⁶⁾. Most amoebocyte lysate reagents are currently licensed by the FDA, meaning that the development and product processes comply with regulatory guidelines and current Good Manufacturing Practice (cGMP) and/or International Organization for Standardization (ISO) standards. Similar quality controls for the development, manufacturing, and master cell banking of recombinant protein reagents are critical from an end-user perspective.




Fig. 3 Comparison of Results of Amoebocyte Lysate and Recombinant Protein Reagents for Endotoxin Panel Testing

Water samples containing endotoxin, collected from independent institutions, were tested with various amoebocyte lysate (■) and recombinant protein reagents (□). The relative endotoxin activities (EU/mL) against RSE were calculated to compare the specificity of each reagent. Values are the mean ± standard error shown in Tables 1 and 2.




Fig. 3 Continued

Table 3 Equality of Variance of Endotoxin Level by Amoebocyte Lysate and Recombinant Protein Reagents

No.	sample	F value ^a	critical value ^b	P value ^c	distribution ^d
<i>Autochthonous endotoxin</i>					
1	<i>Escherichia coli</i> O113:H10:K negative	16.55	15.10	0.04396	not equal variance
<i>Water including endotoxin</i>					
2	Tap water #1	7.509	15.10	0.1294	equal variance
3	Tap water #2	7.742	15.10	0.1243	equal variance
4	Deionized water #1	3.030	15.10	0.3893	equal variance
5	Tap water #3	13.67	15.10	0.05746	equal variance
6	Tap water #4	4.988	15.10	0.2178	equal variance
7	Tap water #5	1.982	15.10	0.6008	equal variance
8	Tap water #6	2.342	15.10	0.5104	equal variance

^a F value was calculated from the ratio of variance from the two groups

^b F critical value is the value where the area is 0.05 when the degree of freedom is (4, 3) in a two-sided test in the F distribution table.

^c P value is the probability that the null hypothesis of equal variances holds.

^d The difference between amoebocyte lysate and recombinant protein reagent groups was considered significant when $P < 0.05$ in a two-sided test.

A further study to compare the ability of amoebocyte lysate and recombinant protein reagents to detect endotoxin from *H. pylori* is in progress.

Acknowledgments

This study was supported by a Research Grant on Testing Methods of the Japanese Pharmacopoeia from the Pharmaceutical and Medical Device Regulatory Science Society of Japan.

Conflicts of Interest

O.M., M.S. and S.S. are employees of Hyglos/bioMérieux Japan, Ltd.; K.O. is an employee of J.K. International, Inc.; T.K., H.F. and M.K. are employees of FUJIFILM Wako Pure Chemical Corporation; T.M. is an employee of Lonza; T.O., H.M. and N.O. are employees of Seikagaku Corporation; D.I., H.S. and Y.T. are employees of Veritas Corporation; and M.T. is an employee of Charles River. The other authors declare that they have no conflict of interest.

References

- 1) Tanamoto, K. Endotoxin and the quality control of medicine. *Bull. Natl. Inst. Health Sci.* 2008, **126**, p.19-33.
- 2) The Ministry of Health, Labour and Welfare, Japan. 4.01 Bacterial Endotoxins Test. The Japanese Pharmacopoeia, Eighteenth Edition. 2021, p.124-127.
- 3) European Pharmacopoeia. 2.6.14. Bacterial endotoxins. 2016, 8.0, p.194-198.
- 4) United States Pharmacopeia. <85> Bacterial endotoxins test. 2019, **42**, p.6434-6438.
- 5) Ding, J.L.; Chai, C.; Pui, A.W.M.; Ho, B. Expression of full length and deletion homologues of *Carcinoscorpius rotundicauda* Factor C in *Saccharomyces cerevisiae*: immunoreactivity and endotoxin binding. *J. Endotoxin Res.* 1997, **4**, p.33-43.
- 6) Loverock, B.; Simon, B.; Burgenson, A.; Baines, A. A recombinant factor C procedure for the detection of gram-negative bacterial endotoxin. *Pharmacopoeial Forum.* 2010, **36**, p.321-329.
- 7) Stevens, I.; Ogura, N.; Kelley, M.; D'Ordine, R. L.; Mizumura, H.; Oda, T.; Akiyoshi, J.; Jahngen, E. G. Advanced Recombinant Cascade Reagent PyroSmart NextGen[®] for Bacterial Endotoxins Test as Described in the Pharmacopoeias. *BPB Reports.* 2022, **5**, p.105-114.
- 8) U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Guidance for industry-pyrogen and endotoxins testing: questions and answers. 2012. <http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm314718.htm>.
- 9) United States Pharmacopeia. <1225> Validation of compendial procedures. 2019, **42**, p.8046-8050.
- 10) European Pharmacopoeia. 2.6.32. Test for bacterial endotoxins using recombinant Factor C. 2021, 11.0, p.252-254.
- 11) The Ministry of Health, Labour and Welfare, Japan. General Information <G4-4-180> Bacterial

- Endotoxins Test and Alternative Methods using Recombinant Protein-reagents for Endotoxin Assay. The Japanese Pharmacopoeia, Eighteenth Edition. 2021, p.2691-2693.
- 12) Bolden, J.; Knight M.; Stockman S.; Omokoko B. Result of harmonized endotoxin recovery study protocol evaluation by 14 BioPhorum Operations Group (BPOG) member companies. *Biologicals*. 2017, **48**, p.74-81.
 - 13) Bolden, J.; Smith K. Application of Recombinant Factor C Reagent for the Detection of Bacterial Endotoxins in Pharmaceutical Products. *PDA J Pharm Sci and Tech*. 2017, **71**, p.405-412.
 - 14) Muroi M.; Ogura N.; Mizumura H.; Aketagawa J.; Oda T.; Tanamoto K. Application of a Recombinant Tree-Factor Chromogenic Reagent, PyroStar, for Bacterial Endotoxins Test Filed in the Pharmacopeias. *Bio. Pharm. Bull*. 2019, **42**, p.2024-2037.
 - 15) Kelly M.; Stevens I.; Marchessault N.; Akiyoshi J.; Jahngen, E. G. Evaluation of a Recombinant Cascade Reagent PyroSmart NextGen[®] and Limulus Amoebocyte Lysate Equivalency in a Plate and Tube Reader for Bacterial Endotoxins Testing. *BPB Reports*. 2023, **6**, p.11-15.
 - 16) Kelley, M.; Stevens, I.; Oda, T.; Akiyoshi, J.; Jahngen, E. G. A Demonstration of the Validation Process for Alternative Endotoxin Testing Methods Using PyroSmart NextGen[®] Recombinant Cascade Reagent. *BPB Reports*. 2023, **6**, p.68-75.
 - 17) Kikuchi, Y.; Haishima, Y.; Fukui, C.; Murai, T.; Nakagawa, Y.; Ebisawa, A.; Matsumura, K.; Ouchi, K.; Oda, T.; Mukai, M.; Masuda, T.; Katto, Y.; Takasuga, Y.; Takaoka, A. Collaborative Study on the Bacterial Endotoxins Test Using Recombinant Factor C-Based Procedure for Detection of Lipopolysaccharides (Part 1). *Pharmaceutical and Medical Device Regulatory Science*. 2017, **48**, p.252-260.
 - 18) Kikuchi, Y.; Haishima, Y.; Fukui, C.; Nakagawa, Y.; Ebisawa, A.; Morioka, T.; Matsumura, K.; Ouchi, K.; Uchida, K.; Martinez, O.; Oda, T.; Mukai, M.; Masuda, T.; Tsukihashi, Y.; Takasuga, Y.; Takaoka, A. Collaborative Study on the Bacterial Endotoxins Test Using Recombinant Factor C-Based Procedure for Detection of Lipopolysaccharides (Part 2). *Pharmaceutical and Medical Device Regulatory Science*. 2018, **49**, p.708-718.
 - 19) Rudbach, J.A.; Akiya, F.I.; Elin, R.J.; Hochstein, H.D.; Luoma, M.K.; Milner, E.C.; Milner, K.C.; Thomas, K.R. Preparation and properties of a national reference endotoxin. *J Clin Microbiol*. 1976, **3**, p.21-25.
 - 20) Kobayashi, Y.; Takahashi, T.; Shibata, T.; Ikeda, S.; Koshiba, T.; Mizumura, H.; Oda, T. Kawabata, S. Factor B is the second lipopolysaccharide-binding protease zymogen in the horseshoe crab coagulation cascade. *J. Biol. Chem*. 2015, **290**, p.19379-19386.